Opendata, web and dolomites


The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.

Total Cost €


EC-Contrib. €






 HbMP-700 project word cloud

Explore the words cloud of the HbMP-700 project. It provides you a very rough idea of what is the project "HbMP-700" about.

powder    standard    preclinical    plan    military    sufficient    severe    total    conduct    sales    months    surgery    humans    types    proof    stored    healthcare    conducting    subsequently    technological    gmp    rbc    critical    peak    cc    patented    risk    mio    manufacturing    unlimited    supply    accidents    25    contamination    countries    weeks    good    human    treat    introduction    patient    bn    shortages    lyophilized    economic    purification    laboratory    trial    safety    blood    demand    transformed    disasters    bears    hbmp    gcp    annually    source    slaughterhouse    few    trials    world    match    nearly    market    regulatory    donors    compliant    global    malignancies    feasibility    infections    sme    transfusions    conflicts    adding    substitute    natural    infection    voluntary    extracted    35    patients    frequent    85    victims    markets    representing    15nb    compensate    700    ery    excellent    first    bovine    leads    afford    red    clinical    cell    develops    care    donor    situation    business    haematological   

Project "HbMP-700" data sheet

The following table provides information about the project.


Organization address
city: BERLIN
postcode: 13125
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CC-ERY GMBH DE (BERLIN) coordinator 50˙000.00


 Project objective

CC-Ery GmbH develops HbMP-700, the world’s first substitute for human blood as a source for red blood cell (RBC) transfusions. 85 Mio. RBC transfusions are used p.a., representing a 10-15nb€ market. They are used to compensate for blood loss during surgery, treat patients with haematological malignancies, as well as victims of accidents, natural disasters, and military conflicts. The only source for RBC transfusions today are voluntary human blood donors. This leads to frequent supply shortages in the EU and other major healthcare markets. Donor blood must match patient blood. It can only be stored a few weeks, adding to the critical supply situation. Developing countries face a more severe situation as they cannot afford the standard of care of the developed world. In addition, human blood bears the risk of contamination with infections. HbMP-700 is extracted from bovine blood – a nearly unlimited, low cost supply source. It is transformed by a patented purification and manufacturing method to a lyophilized powder that is as effective as RBC transfusions from human blood, but bears no risk of infection, can be stored for months, and can be given to patients of all blood types. Bovine blood from one major EU slaughterhouse is sufficient to produce enough HbMP-700 to supply global demand for RBC transfusions. CC-Ery implemented the manufacturing method on a laboratory scale and is currently conducting preclinical trials, so far with excellent results. The objective of the SME Phase I project is to develop a business plan for the market introduction of HbMP-700. For this, a technological, regulatory, and economic feasibility analysis will be conducted. In Phase II, it is planned to build up a GMP (Good Manufacturing Practice) compliant manufacturing process and subsequently conduct a GCP (Good Clinical Practice) safety and proof of concept trial in humans. Total cost to market is estimated to be € 25-35 Mio. Peak sales are estimated to be more than € 1 bn. annually.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HBMP-700" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HBMP-700" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More